Where Will AbbVie Be in 5 Years?

Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine, and AbbVie (NYSE: ABBV) is no exception. Nonetheless, the next five years will likely see it growing faster than the last five years, and shareholders are apt to benefit.Here's where this company will be going, and where it's probably going to end up.In the next five years, expect AbbVie to continue to compete in the disease areas that its pipeline and product mix are currently heavily focused around: immunology, neuroscience, and oncology. It'll also likely continue to compete at a much smaller scale in aesthetics, eye medicines, and a grouping of other areas like infectious disease, but these efforts are ancillary at most. Given the 14 early-stage oncology programs it has that are currently in clinical trials, cancer drugs will probably be more important to the top line than they have been in the past.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool